June 24th 2025
Frequent exposure to cannabis and e-cigarette posts on social media is linked to increased teen cannabis and dual substance use, according to a study published in JAMA.
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Transdermal delivery of methylphenidate passes a test of efficacy in ADHD
June 8th 2006New research reported at the annual meeting of the American Psychiatric Association in Toronto in May shows that Shire Pharmaceutical Group's methylphenidate transdermal system (Daytrana) appears a safe and well-tolerated alternative to OROS methylphenidate, and is equally efficacious.
ADHD study supports lower lead exposure limits
May 1st 2006A new study on potential interactions between genetic and environmental factors in ADHD suggests that current limits on lead exposure are too high. Lead exposure below the current limits allowed by Environmental Protection Agency regulations produced measurable impairment of executive functions, especially in boys, who have a specific variation in the DRD4 dopamine receptor gene.
Study: Ritalin effective in preschoolers with ADHD
October 10th 2005The longest and most complex study of methylphenidate (Ritalin) in preschool children shows that it can be safe and effective for some children in that age group who have attention deficit hyperactive disorder (ADHD), according to the study's lead author.
The question of the day: Is there an autism epidemic?
October 8th 2005The answer? We don't really know, according to Craig Newschaffer, PhD, associate professor at the Johns Hopkins School of Public Health. But fears of an autism epidemic have been overblown by the press and advocacy groups, said Dr. Newschaffer, speaking at the American Academy of Pediatrics National Conference and Exhibition today in Washington, D.C.
FDA extends indication for ADHD treatment formulation to adolescent years
October 5th 2005The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.
Let's get discussion of what causes autism back on track!
September 1st 2005Lately, I've spent a lot of time talking about the alleged link between thimerosal in pediatric vaccines and autism. Most of you have been asked by parents whether immunizations pose a risk of autism as well, and some parents are so frightened by rumors, press reports, and information on the World Wide Web that they forgo immunizations for their children altogether.
Where we are, and how well we can succeed, at treating ADHD
December 1st 2003At pediatricians' disposal today are numerous formulations of approved medications for ADHD--traditional psychostimulants and newer agents. We also have developed an appreciation of the value of a multipronged approach to this chronic disorder.